Proton and carbon ion radiotherapy for primary brain tumors delivered with active raster scanning at the Heidelberg Ion Therapy Center (HIT): early treatment results and study concepts by Stefan Rieken et al.
RESEARCH Open Access
Proton and carbon ion radiotherapy for primary
brain tumors delivered with active raster
scanning at the Heidelberg Ion Therapy Center
(HIT): early treatment results and study concepts
Stefan Rieken1,3*, Daniel Habermehl1, Thomas Haberer2, Oliver Jaekel2, Jürgen Debus1 and Stephanie E Combs1
Abstract
Background: Particle irradiation was established at the University of Heidelberg 2 years ago. To date, more than
400 patients have been treated including patients with primary brain tumors. In malignant glioma (WHO IV)
patients, two clinical trials have been set up-one investigating the benefit of a carbon ion (18 GyE) vs. a proton
boost (10 GyE) in addition to photon radiotherapy (50 Gy), the other one investigating reirradiation with escalating
total dose schedules starting at 30 GyE. In atypical meningioma patients (WHO °II), a carbon ion boost of 18 GyE is
applied to macroscopic tumor residues following previous photon irradiation with 50 Gy.
This study was set up in order to investigate toxicity and response after proton and carbon ion therapy for gliomas
and meningiomas.
Methods: 33 patients with gliomas (n = 26) and meningiomas (n = 7) were treated with carbon ion (n = 26) and
proton (n = 7) radiotherapy. In 22 patients, particle irradiation was combined with photon therapy. Temozolomide-
based chemotherapy was combined with particle therapy in 17 patients with gliomas. Particle therapy as
reirradiation was conducted in 7 patients. Target volume definition was based upon CT, MRI and PET imaging.
Response was assessed by MRI examinations, and progression was diagnosed according to the Macdonald criteria.
Toxicity was classified according to CTCAE v4.0.
Results: Treatment was completed and tolerated well in all patients. Toxicity was moderate and included fatigue
(24.2%), intermittent cranial nerve symptoms (6%) and single episodes of seizures (6%). At first and second follow-
up examinations, mean maximum tumor diameters had slightly decreased from 29.7 mm to 27.1 mm and 24.9
mm respectively. Nine glioma patients suffered from tumor relapse, among these 5 with infield relapses, causing
death in 8 patients. There was no progression in any meningioma patient.
Conclusions: Particle radiotherapy is safe and feasible in patients with primary brain tumors. It is associated with
little toxicity. A positive response of both gliomas and meningiomas, which is suggested in these preliminary data,
must be evaluated in further clinical trials.
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Background
Despite continuously evolving extensive treatment con-
cepts, primary brain tumors such as low grade and high
grade gliomas, as well as meningiomas have not ceased
to cause high morbidity and lethality due to biological
aggressiveness or location in close proximity to critical
structures. Radiotherapy is implemented in most glioma
and many meningiomas therapy regimes and has been
shown to significantly improve local control and prolong
survival [1-3]. However, treatment results are still not
satisfying, and most patients show tumor recurrence
during the course of follow-up.
Particle irradiation is characterized by unique physical
and biological properties which allow escalated dose
deposition with steep gradients. Therefore, high local
doses can be applied, while normal structures may be
spared, and tumors in close vicinity of dose-limiting
normal organs at risk may be treated more efficiently
with higher doses. A clinical phase I/II trial from Japan
has suggested high efficiency of carbon ion treatment
for malignant gliomas with low toxicity [4]. For menin-
giomas, early data from our institution have demon-
strated very promising results for atypical and anaplastic
variants [5]. This has led to initiation of several trials
that investigate a potential benefit of particle irradiation
for both meningioma and gliomas [6-8].
The Heidelberg Ion Therapy Center (HIT) started
patient treatment in November 2009 and has until now
treated more than 250 patients with chordomas, chon-
drosarcomas, head and neck tumors, and primary brain
tumors including both high and low grade gliomas and
meningiomas. Carbon and proton irradiations have both
been delivered as first radiotherapies but also as reirra-
diations [9,10]. Treatments so far were tolerated well
with only moderate toxicity [11].
In the present manuscript we describe our currents
institutional planning and treatment procedures in the
management of particle irradiation for gliomas and
meningiomas and analyse toxicity and early outcome of
33 patients treated within novel multimodal treatment
concepts.
Materials and methods
Patient characteristics are summarized in Table 1.
Between November 2009 and January 2011, we treated
33 patients with gliomas and meningiomas at the HIT.
Histological diagnosis was glioblastoma multiforme
(GBM) in 18 (54.5%), anaplastic glioma in 3 (9.1%), low
grade glioma in 5 (15.2%), and meningioma in 7 (21.2%)
patients. Median age was 42 years (range 7-77 years)
with 3 children ≤ 18 years included. Ten patients were
female (30.3%), and 23 were male (69.7%). All patients
provided written informed consent after thorough
information about treatment concepts and possible side
effects. For all study concepts, approval of the ethics
committee of the University of Heidelberg had been
obtained, as well as a positive votum by the Bundesamt
für Strahlenschutz (BfS).
Particle treatment for meningiomas was conducted in
atypical meningioma patients (WHO °II) according to
the MARCIE-protocol (7) following incomplete resec-
tion and was carried out as mixed modality irradiation
with carbon ion boosts to the macroscopic tumor (6 × 3
GyE). For benign meningiomas, proton irradiation was




patient number 33 100
gender female 10 30.3
male 23 69.7




pediatric patients [≤ 18 years] 3 9.1
histology glioma 26 100
WHO ° II 5 19.2
WHO ° III 3 11.5
WHO ° IV 18 69.2
meningioma 7 100
WHO ° I 3 43
WHO ° II 3 43
WHO ° III 1 14
radiotherapy mixed modality 22 66.6
[12C] only 6 18.2
[1H] only 5 15.2
particle reirradiation 7 21.2
[ml]
mean particle volume [particle only, ml] 65.64
mean particle volume [particle boost, ml] 69.29
mean photon volume [particle boost, ml] 252.65
[Gy]
range carbon total dose 18-45
range proton total dose 10-57.2
range photon total dose 50
[mm]
Tumor diameter before RT 29.7
Tumor diameter at first follow-up 27.1
Tumor diameter at second follow-up 24.9
[n] [%]
relapse meningioma 0 0
relapse glioma WHO ° II 0 0
relapse glioma WHO ° III/° III 9 42.3
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In glioma patients with macroscopic tumor residues,
carbon ion (6 × 3 GyE) vs. proton boosts (5 × 2 Gy) fol-
lowing previous photon radiotherapy (50 Gy) are being
investigation within the CLEOPATRA trial (8). Reirra-
diation with carbon ions following a dose escalation
schedule and starting a 10 × 3 GyE is offered to patients
with benign and malignant unifocal glioma recurrences
(WHO ° I-IV) (6).
Prior to treatment, individual fixation devices (Scotch-
cast-and Thermoplast-masks) were prepared to ensure
precise daily positioning. Treatment planning was based
on 3 mm CT slices fused with contrast agent-enhanced
MRI. In case of gliomas, 18F-FET-PET/CT examinations
were performed in order to support delineation of target
volumes and to identify high-risk areas, whereas for
meningiomas DOTATOC-PET/CT examinations were
used to identify metabolically active tumor tissues by
means of a lesion-versus-normal ratio (L/N ratio). Mean
L/N ratio was 2.82.
For high-grade gliomas, a boost was defined with a
gross tumor volume (GTV) including the contrast-enha-
cing lesion on MRI as well as the FET-PET-positive
areas, adding a 0.5 cm safety margin for the clinical tar-
get volume (CTVboost). The CTV for photon radiother-
apy (CTVphotons) was defined as the T2-hyperintense
areas adding 2-3 cm safety margins for microscopic
spread.
For high risk meningioma, the GTV was defined as
the contrast-enhancing areas on MR-imaging as well as
the DOTATOC-positive areas, adding 5 mm margin for
the CTVboost. The CTVphotons was defined adding 2-3
cm to encompass potential microscopic spread.
The planning target volume (PTV) for particle therapy
was calculated with a margin of 3 mm, for photon
radiotherapy with a margin of 5 mm.
For particle boost irradiation, median boost volumes
were 69.29 ccm, with additional photon volumes of
252.65 ccm. For sole particle treatment, the planning
target volume encompassed a median volume of 65.64
ccm.
Seven patients were treated with protons, and 26
patients received carbon ion radiotherapy. Protons were
chosen in case of children, low-grade meningioma and
glioma and in one glioblastoma patient following rando-
misation (8). Single proton doses ranged from 1.8 to 2
GyE with total doses of 10-57.2 GyE. Single carbon ion
doses were 3 GyE with total doses of 18-45 GyE. In case
of either carbon ion or proton boost irradiation for
either primary high grade gliomas [12] or high grade
meningiomas [7], photon irradiation with 50 Gy was
combined. In 7 patients, particle therapy was performed
as reirradiation for recurrent tumors (2 × meningiomas,
5 × gliomas). Reirradiation for malignant gliomas was
conducted according to a study protocol using carbon
ions without combining with photon irradiation [6].
Two patients with recurrent meningiomas were treated
with carbon ion total doses of 36 and 45 GyE. In 17
patients, particle treatment was combined with temozo-
lomide chemotherapy at doses of 75 mg/m2 body-sur-
face-area 7 days per week during radiotherapy (1).
First clinical and MRI follow-up examination were
performed six weeks after irradiation and every two
months hereafter. Tumor response was assessed on the
basis of T1-weighted MRI scans, and recurrence was
diagnosed according to the Macdonald criteria. Acute
toxicity arising during the first 90 days after radiother-
apy completion was classified according to CTCAE v4.0.
Results
Workflow
Mask fixations and planning examinations were com-
pleted about 2 weeks prior to the beginning of treat-
ment. CT scans were performed without contrast agent
to prevent miscalculation of particle range. For both
morphological and functional identification of vital
tumor tissue, gadolinium-enhanced MRI and PET/CTs-
tracing either amino acid transporters in gliomas or
somatostatin receptors in meningiomas-were performed
and fused to the planning CTs. Target volumes included
any contrast agent-enhanced structure in T1-weighted
MRI-examination and were adapted to additionally
include any region of increased PET tracer uptake. PET-
associated target volume modifications caused expansion
of target volumes in most cases of extensive tumor for-
mations (Figure 1 and 2). Median volumes for particle
treatment ranged from 17.16 to 434.98 ml with median
volumes of 65.64 ml in case of sole particle treatment
Figure 1 Extensive glioblastoma multiforme in a 62-year-old
man. Contrast-agent enhanced CT and MRI scan were fused with a
FET-PET/CT examination and used to calculate a two-beam carbon
ion radiotherapy plan.
Rieken et al. Radiation Oncology 2012, 7:41
http://www.ro-journal.com/content/7/1/41
Page 3 of 7
and 60.29 ml, when particle treatment was combined
with photon radiotherapy. Tumor size itself was not a
determining factor when allocating patients to particle
treatment. However multifocality or systemic metastases
for example via CSF dissemination were considered as
contraindications for particle irradiation which in gen-
eral was applied when local relapse was deemed the
most likely threat to our patients. Figure 1, 2, 3, and 4
demonstrate four patients with malignant gliomas (Fig-
ures 3 and 1) and atypical meningiomas (Figures 4 and
2) of limited (Figures 3 and 4) and widespread (Figures
1 and 2) extension. Planning CT examinations (Figure 1,
2, 3, and 4; left) are fused with contrast-enhanced MRI
and PET examination (Figure 1, 2, 3, and 4; central left
and right) to generate particle irradiation treatment
plans (Figure 1, 2, 3, and 4; right).
Toxicity
Treatment was performed without interruptions in any
patient. Acute toxicity was moderate and comprised low
grade edema-related headache (14.7%) and increased
tiredness during the day (24.2%). In two patients, unver-
ified intensifications of pre-existing cranial nerve palsies
were reported (1 × reduced visual acuity, 1 × reduced
acoustic acuity). Visual impairment quickly recovered
after oral administration of corticosteroids. Two patients
suffered from single and self-limiting seizures during
treatment. Apart from one temozolomide-related throm-
bocytopenia < 20,000/nl, no toxicities exceeding CTCAE
v4.0 grade II were observed. The addition of chemother-
apy was tolerated very well and did not enhance treat-
ment toxicity.
Response
Median follow-up was 4.5 months. Early assessment of
tumor response 6 and 12 weeks after radiotherapy
demonstrated a slight, but not yet significant decrease in
tumor diameters from 29.7 mm to 27.1 mm and 24.9
mm, respectively. Nine of eighteen glioblastoma patients
(50%) suffered from progression of disease following
particle radiotherapy, causing death in 8 patients
(44.4%). Among these, 5 patients developed tumor
recurrence within the particle radiotherapy fields
Figure 2 Multifocal diffusely spreading atypical meningioma in
a 55-year-old woman. Contrast-agent enhanced CT and MRI scan
were fused with a DOTATOC-PET/CT examination and used to
calculate a two beam carbon ion radiotherapy plan.
Figure 3 Glioblastoma multiforme in the right frontal lobe of a
48-year-old woman. Contrast-agent enhanced CT and MRI scan
were fused with a FET-PET/CT examination and used to calculate a
single beam carbon ion radiotherapy plan.
Figure 4 Nodular atypical meningioma in a 50-year-old man.
Contrast-agent enhanced CT and MRI scan were fused with a
DOTATOC-PET/CT examination and used to calculate a single beam
carbon ion radiotherapy plan.
Figure 5 Tumor response at 12 weeks after particle therapy in
3 individual glioblastoma patients. A: reirradiation of a right
frontal glioblastoma relapse with 10 × 3 GyE. B: combined photon/
proton radiotherapy (total dose 60 GyE) with a proton boost
irradiation with 5 × 2 GyE. C: combined photon/carbon ion
radiotherapy (total dose 68 GyE) with a carbon ion boost irradiation
with 6 × 3 GyE.
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(27.7%). There was no relapse in WHO °II/°III-glioma or
meningioma patients during the present follow up. At
the time of this analysis, neither age, sex, nor modality
(12C vs. 1H) were significant indicators of response. Fig-
ure 5 demonstrates 3 individual glioblastoma patients
who underwent different regimes of proton and carbon
ion irradiation and who responded well to particle irra-
diation (Figure 5). After carbon ion RT either for reirra-
diation of recurrent glioblastoma (Figure 5A, 30 GyE) or
for boost irradiation (Figure 5C, 18 GyE) following prior
photon radiotherapy with 50 Gy photons, a significant
decrease in tumor size, but also significantly reduced
contrast agent uptake can be noted. Figure 5B shows a
47-year old female glioblastoma patient, who received a
10 GyE proton boost after irradiation with 50 Gy
photons and who responded very well without suffering
from treatment-related toxicities.
Discussion
In the present manuscript we analysed daily workflow in
planning and conduction of particle radiotherapy for
brain tumors as well as toxicity and early response in 33
patients treated at the department of Heavy Ion Therapy
(HIT) at the university hospital of Heidelberg.
The HIT started patient treatment in November 2009
and has treated more than 250 patients until today [9].
Treatment has been integrated into daily routine at the
Department of Radiation Oncology and particle radio-
therapy has been tolerated well with only moderate toxi-
city [11]. In primary CNS malignancies particle
irradiation has proven beneficial outcome at low toxicity
including malignant gliomas [4,13] and meningiomas
[5]. Besides sole particle concepts, also combined parti-
cle-photon regimes have been established and have
yielded promising results in gliomas [14] and meningio-
mas [15] in terms of toxicity, local control, and survival.
At the HIT, several clinical trials have recently started
accrual and will systematically analyse the impact of
particle irradiation in both glioma and meningioma
[6,7,12]. Before initiation of these studies, 33 patients
have completed particle treatment and are being
reported here.
Planning examination included functional biological
imaging of tumor cell spread and viability by means of
radiolabelled tracers. 18F-FET has been shown to pos-
sess a sensitivity of 94% in the diagnosis of malignant
gliomas [16], despite its limited specificity that compares
well to 18F-FDG [17]. Several authors have demon-
strated a positive and prognostically relevant effect of
considering amino acid uptake for target volume defini-
tion and have shown equivalence of both 11C-methio-
nine and 18F-tyrosine in the evaluation of malignant
gliomas [18-20]. Also, in menigioma patients functional
imaging has been demonstrated to improve target
volume delineation [21,22].
Carbon ion radiotherapy was offered to patients with
high grade tumors. Carbon ion irradiation exerts very
distinct radiobiological and radiophysical effects that
translate into very precise dose deposition with
increased biological effectiveness while simultaneously
sparing closely neighbored organs at risk [23]. The ben-
eficial effect of carbon ion radiotherapy in both malig-
nant glioma and meningioma patients has been shown
both preclinically [24,25] and in preliminary clinical
trials [4,5]. Proton therapy was offered to children and
patients with low-grade gliomas and meningiomas,
where previous clinical trials have already demonstrated
a beneficial impact [26-28].
Both carbon and proton treatments were tolerated
well without differences regarding toxicity. For reason of
modality selection, assigning low grade tumor patients
to proton irradiation, these patients tended to fare better
than patients treated with carbon ions.
As previously published by our group [11], acute sides
effects were rare in brain tumor patients. Cranial nerve
palsies as reported under particle irradiation [29]
occurred temporarily in two patients. In one patient,
reduction in visual acuity improved after administration
of oral corticosteroids. In one further patient, who com-
plained about hearing loss, no vestibulocochlear mis-
function could be verified. General symptoms of CNS
irradiation such as tiredness, reduced consciousness and
dizziness occurred in 24.2%. Altered cognitive function
affecting activities of daily life was reported in four
patients (12.1%), all of whom were diagnosed with
malignant glioma.
Only little time since treatment completion has
elapsed and too little patient numbers have been
included to provide reliable information about tumor
response following carbon ion or proton RT. At this
point, a slight but not yet significant decrease in median
tumor size was observed. Nine patients suffered from
tumor relapse following particle irradiation, including 5
(15.2%) with tumor recurrences within the particle irra-
diation fields indicating high tumor cell intrinsic radio-
resistance. Diagnosis was glioblastoma in all of them,
and 3 patients (60%) had been treated with prior photon
therapy and were patients for particle reirradiation. We
failed to identify predictors of response in this heteroge-
neous patient group. However, even within this little
cohort and not a surprise to the audience, it became
clear that meningioma patients are characterised by
higher progression free survival rates and thus a better
prognosis than glioma patients. Miyatake et al. investi-
gated toxicity and response of 6 patients with recurrent
malignant meningiomas undergoing reirradiation by
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means of boron neutron capture therapy, which also
represent a high LET therapy, and found radiological
response in all patients after a time period of 7 to 13
months [30]. This strengthens the concept of high LET
radiotherapies in patients with malignant meningiomas.
Further prognostically relevant factors remain to be
identified in future clinical studies. In addition, longer
follow-up periods are mandatory to evaluate normal tis-
sue function after particle treatment and to solidify indi-
vidual patterns of response when comparing proton and
carbon ion treatments.
Conclusion
Particle irradiation for primary brain tumors is safe and
well tolerable. For adequate target volume delineation,
multimodality imaging is helpful. Tumor response must
be addressed in further clinical trials.
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